Only now, more than a year after COVID-19 infection rates first hit peak levels and in the knowledge that receptors for SARS-CoV-2 are present in the ovary, are we able to assess the effect of the virus on reproductive function. Now, a new study has shown that the ovarian reserve of women previously infected with the virus was not adversely affected, and that their chance of success from fertility treatment remained as it was before infection.
The study, which monitored hormone levels in women having IVF at one of 11 clinics in the IVI group in Spain between May and June 2020, is described today by Dr. Maria Cruz Palomino from IVI Madrid at the online annual meeting of ESHRE.
All the women in the study had baseline hormone measurements before starting treatment, which included measurements of anti-Mullerian hormone (AMH, as a marker of ovarian reserve). AMH has become a widely used measurement in fertility clinics in recent years, able to predict how patients might respond to ovarian stimulation in IVF—although its reliability as a marker of general female fertility is more disputed.
The study included 46 patients having IVF whose baseline measurements of AMH suggested they would be normal or low responders to ovarian stimulation when treatment began. “Generally,” said Dr. Palomino, “the data showed no variation in AMH levels before and after SARS-CoV-2 infection, and we could assume that the chances of success in their fertility treatment remained intact.” However, the results did show a slight decline in AMH measurements in those predicted to be normal responders, which Dr. Palomino said was not a “radical decrease” and unlikely to compromise ovarian reserve—nor, she added, “can we attribute this variation to SARS-Cov-2 infection”.
Several studies reported so far have been reassuring about the effect of COVID-19 infection on female fertility, and this provides further reassurance for those planning fertility treatment with IVF. Experts have described intrauterine infection via placental or congenital routes as unlikely, and reported that perinatal infection found at and after delivery was a more likely explanation for any neonatal infection.
This, as Dr. Palomino explains, was a small study and not robust enough for emphatic public health conclusions, but it does join others in suggesting that ovarian function, as reflected in AMH measurements, is not affected by SARS-Cov-2 infection. There have been concerns because the virus invades its target cells by binding to the ACE2 receptor, which is widely expressed in the ovaries (as well as the uterus, vagina and placenta). The SARS-CoV-2 virus has been said to interrupt female fertility through regulating ACE2. This has caused some anxiety for women contemplating fertility treatment, and this latest study suggests that, while there was a variation in levels of AMH as a marker of ovarian reserve, this variation appeared dependent on patient response to ovarian stimulation, not on previous infection. “Nevertheless,” said Dr. Palomino, “we could assume that the chances of success of fertility treatment remain intact.” The results reflect those of a recent study from Wuhan, China, which similarly found that average sex hormone and AMH concentrations of women of child-bearing age with COVID-19 were not different from those of age-matched controls.
Fertility drugs do not increase breast cancer risk, study finds
See Li K, Chen G, Hou H, et al. Analysis of sex hormones and menstruation in COVID-19 women of child-bearing age. Reprod Biomed Online 2021; 42: 260-267.
Presentation 0-079, Monday 28 June 2021: Could ovarian reserve be affected after SARS-CoV-2 infection?
European Society of Human Reproduction and Embryology
Previous infection with COVID-19 does not affect the chance of success in IVF (2021, June 28)
retrieved 28 June 2021
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no
part may be reproduced without the written permission. The content is provided for information purposes only.
This blog is for information purposes only. The content is not intended as medical advice, diagnosis, or treatment. Should you have a medical or dermatological problem, please consult with your physician. None of the information or recommendations on this website should be interpreted as medical advice.
All product reviews, recommendations, and references are based on the author’s personal experience and impressions using the products. All views and opinions are the author’s own.
This blog post may contain affiliate links. An affiliate link means we may earn a commission if you click on a link and make a purchase, without any extra cost to you.
Please see our Disclaimer for more information.